Gelatex

Market position

Gelatex describes itself as a materials technology company that has changed how nanofibers are produced, and aims to act as a catalyst for nanofiber adoption in clean food, medical applications and sustainable materials. Management acknowledges that other companies worldwide offer nanofibers for cell growth, generally using electrospinning, but argues that scalability and creating a favourable environment for cell culture and tissue formation remain the key constraints, and claims to have developed the world's most powerful nanofiber production technology. Competing approaches cited for cultured-meat fiber production include electrospinning and 3D printing, which the company characterises as more expensive.

Gelatex's stated differentiation rests on its patented halospinning process (US patent 11,697,892), which it describes as a non-electrostatic, nozzle-based solution-spinning method delivering substantially higher production volumes and lower cost than century-old electrospinning technology. A second claimed advantage is material morphology: whereas electrospun materials confine cells to the surface, Gelatex's more porous, self-standing structure permits cell migration into the material and nutrient transport to interior cells, enabling 3D tissue formation. The company also cites cost: it says nanofibrous scaffolds that previously cost about €100,000 per kilogram can be produced for under €1,000 per kilogram, a reduction it links to a roughly 90% cut in cell-cultured meat production cost, with further price declines projected over a decade.

Technology

The core technology is halospinning, a patented high-throughput, nozzle-based, non-electrostatic-field solution-spinning method for making polymer nanofibers, covered by US patent 11,697,892 for a method and device for producing polymer fibers, with a patent application filed in 2020. The company states halospinning is fundamentally faster than electrospinning and allows continuous, scalable production of self-standing nanofibrous material supplied in rolls. Fiber diameters range from 0.1 to 10 μm (materials described as 100 times smaller than a human hair, with cited ranges of 100 nm to 4 μm) and material thickness from 0.1 to 400 g/sq.m, with 3 g/sq.m possible without a substrate. The process is compatible with many polymers and solvents — bio-based options include gelatin, alginate, chitosan, zein, hyaluronic acid and CMC, and synthetic options include PVP, PVOH, PLGA, PCL, SAN, PAN, PU, PA6 and PEG — and supports nanocomposites, addition of pharmaceutical active ingredients, 3D-shaped materials, lamination, coatings and post-treatments. Material properties such as absorption and degradation rate, controlled active-ingredient release, moisture and gas exchange and antimicrobial behaviour can be tuned via formulation.

Go-to-market

Gelatex sells to other companies through service offerings (contract development, contract manufacturing and planned technology licensing) and through partnerships rather than by commercialising its own end products. Its Gelacell cell-culture product line is distributed via distributors, with most sales abroad. The company says it is actively seeking cooperation partners to bring new products or services to market and has cited wound-treatment products under development with partners. Participation in accelerator programmes, including The Heritage Group Accelerator Powered by Techstars, was used to build industry connections and investor access.

Customers are companies and research organisations needing nanofibrous materials: cultured meat and cellular agriculture producers, pharmaceutical and life-science users of 3D cell culture, medical and wound-care product developers, and users in filtration, energy, cosmetics and advanced textiles. Buyers include universities (in small quantities) and partner firms developing end products such as wound-treatment devices. Earlier, as a leather-alternative textile maker, the company targeted fashion and luxury brands.

Geography

Gelatex is headquartered in Tallinn, Estonia, where it was registered in 2016, and is a member of Tehnopol's Healthtech Community and Innovation Leaders Club, having participated in the Startup Incubator's accelerator. It took part in a three-month accelerator in Indianapolis, USA in 2019. Its team is described as multinational, and most sales of its cell-culture products are to customers outside Estonia, with Estonian universities buying only small quantities. The company states it partners with universities, researchers, startups and corporations worldwide.

History

The company traces its origin to 2016, when its founders won the ClimateLaunchpad competition with the idea of producing leather-like textiles from gelatin nanofibers, and Gelatex Technologies OÜ was registered in Tallinn. In its first years it positioned itself as a materials science startup making a non-toxic, eco-friendly textile chemically identical to leather from gelatin derived from leather- and meat-industry waste, supported by the Estonian Ministry of Environment, Climate-KIC, Prototron, Enterprise Estonia, Archimedes and the Horizon 2020 SME Instrument. In 2019 Gelatex was selected for the inaugural class of The Heritage Group Accelerator Powered by Techstars in Indianapolis, receiving an initial USD 120,000 investment and seeking access to fashion-industry players and US investors. In 2020 the company pivoted away from leather-like textiles to supplying nanofibrous materials to other companies and filed a patent application on its halospinning method; management considers 2021 — when the first significant funding round was raised and the current team assembled — the start of today's Gelatex. Development in the preceding four to five years was funded through grants and competitions rather than equity investment. Subsequent milestones include a €1.2 million seed round in November 2021, an Estonian Applied Research Programme grant for cultured-meat microcarriers (2022-2024), the grant of US patent 11,697,892, and participation from 2025 in the Eurostars-2 SMART lab-grown leather project.

Risks & controversies

The cultured meat sector had not yet scaled at the time of the 2021 seed round, with only Singapore selling cultured meat commercially, making demand for scaffolding materials dependent on that industry's future growth. Cost claims and the projected decline in scaffold pricing to about €20 per kilogram within ten years are company estimates. The business has already undergone one major pivot, abandoning its original leather-like textile product in 2020, and management states it does not currently have the capacity to commercialise products itself, leaving commercialisation dependent on partners. Technology licensing was still described as becoming available in the future rather than operational.